Atara Biosciences Appoints Kanya Rajangam Chief Medical Officer

11:52 EDT 24 Aug 2017 | Xconomy

Atara Biotherapeutics has appointed Kanya Rajangam chief medical officer. Before joining Atara (NASDAQ: ATRA), Rajangam was chief medical officer of Burlingame, CA-based Cleave Biosciences. Atara, based in South San Francisco, CA, expects to start two Phase 3 clinical trials later this year for its lead drug, ATA129, a potential treatment for certain lymphomas.

Original Article: Atara Biosciences Appoints Kanya Rajangam Chief Medical Officer


More From BioPortfolio on "Atara Biosciences Appoints Kanya Rajangam Chief Medical Officer"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...